DeckTherapeutics

Executive Summary

DeckTherapeutics is a preclinical-stage biotechnology company pioneering intravenous omega-3 fatty acid therapeutics for acute hypoxic-ischemic brain injuries, including neonatal encephalopathy (HIE) and ischemic stroke. Founded in 2021 and headquartered in Cambridge, MA, the company leverages its proprietary lead asset, THDG3, a novel semi-synthetic omega-3 fatty acid glyceride emulsion designed to provide rapid neuroprotection. Acute omega-3 fatty acids have demonstrated anti-inflammatory and neuroprotective properties in preclinical models, and THDG3 aims to address high unmet medical needs in conditions where no effective acute therapies exist. The company is currently advancing THDG3 through IND-enabling studies, targeting initial clinical trials in HIE, a devastating condition affecting newborns with limited treatment options beyond therapeutic hypothermia. DeckTherapeutics' approach could also expand into ischemic stroke, a major cause of adult disability, with substantial market potential. While the company has not disclosed funding rounds or valuation, its focused pipeline and validated scientific rationale position it as an emerging player in neuroprotective acute care. However, as a private, early-stage company with no clinical data, DeckTherapeutics faces significant development, regulatory, and commercial risks. Progress depends on successful IND filing, initial safety/tolerability trials, and demonstration of efficacy in proof-of-concept studies.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for THDG3 in HIE40% success
• Q2 2027Phase 1 SAD/MAD Study Initiation35% success
• Q4 2026Preclinical Efficacy Data in Stroke Models50% success